Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

Name: 4th International Homocystinurias Patient-Expert Meeting
Start: 2021-11-30T08:00:00+00:00
End: 2021-11-30T18:00:00+00:00

Aeglea BioTherapeutics, Inc.has announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria. Aeglea initiated a Phase 1/2 clinical trial earlier this year to investigate ACN00177 for the treatment of Homocystinuria. Read the Press Release here.